The Dawson James Small Cap Growth Conference will be held at the Wyndham Grand Hotel, Jupiter FL. The event will showcase discussions, presentations, and keynotes by 30 senior management teams and industry leaders on the latest developments and exciting opportunities in the small-cap segment.
For more information visit:
Conference Website
- 22nd Century Group, Inc.
- Adial Pharmaceuticals, Inc.
- Aditxt Inc.
- Amergent Hospitality Group Inc.
- Anavex Life Sciences Corp.
- Better Choice Company Inc.
- Caladrius Biosciences, Inc.
22nd Century Group, Inc. (NASDAQ: XXII)
22nd Century Group, Inc. (NASDAQ: XXII) is a leading plant biotechnology and intellectual property company focused on improving health and wellness through plant science. 22nd Century uses modern plant breeding technologies, gene-editing, and molecular breeding to deliver value to its customers in the life science and consumer products industries by creating new, proprietary tobacco, hemp/cannabis and hop plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits. 22nd Century was founded to build intellectual property related to nicotine biosynthesis in the tobacco plant and to commercialize its proprietary reduced nicotine content (RNC) tobacco plants, which have become the cornerstone of FDA's comprehensive plan to address the enormous amount of death and disease caused by addiction to smoking. The Company has also begun to leverage its plant science expertise and existing partnerships to create and commercialize new, proprietary hemp/cannabis and hop plants to optimize their genetics and create valuable new intellectual property. For more information, visit the company's website at www.xxiicentury.com
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL)
Adial Pharmaceuticals (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders. For more information, visit the company's website at www.adialpharma.com
Aditxt Inc. (NASDAQ: ADTX)
Aditxt (NASDAQ: ADTX) is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, visit the company's website at www.aditxt.com
Amergent Hospitality Group Inc. (OTCQB: AMHG)
Amergent Hospitality Group Inc. (OTCQB: AMHG) headquartered in Charlotte, NC, Amergent owns, operates, and franchises fast, casual, and full-service restaurant brands, including American Burger Company, BGR - Burgers Grilled Right, Little Big Burger, PizzaRev, and Hooters gaming venue. For more information, visit the company's website at www.amergenthg.com
Anavex Life Sciences Corp. (NASDAQ: AVXL)
Anavex Life Sciences Corp. (NASDAQ: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), successfully completed a Phase 2a clinical trial for Alzheimer's disease and recently a Phase 2 proof-of-concept study in Parkinson's disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. For more information, visit the company's website at www.anavex.com
Better Choice Company Inc. (NYSE: BTTR)
Better Choice Company Inc. (NYSE: BTTR) is a rapidly growing animal health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier and longer lives. They take an alternative, nutrition-based approach to animal health relative to conventional dog and cat food offerings and position their portfolio of brands to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. They have a demonstrated, multi-decade track record of success selling trusted animal health and wellness products and leverage their established digital footprint to provide pet parents with the knowledge to make informed decisions about their pet's health. They sell the majority of their dog food, cat food and treats under the Halo and TruDog brands, which are focused, respectively, on providing sustainably sourced kibble and canned food derived from real whole meat, and minimally processed raw-diet dog food and treats. For more information, visit the company's website at www.betterchoicecompany.com
Caladrius Biosciences, Inc. (NASDAQ: CLBS)
Caladrius Biosciences, Inc. (NASDAQ: CLBS) is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. They are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Their technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.The Company's current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study (www.freedom-trial.com) in the U.S. for the treatment of coronary microvascular dysfunction ("CMD"); CLBS12 (HONEDRA® in Japan), recipient of orphan designation for Buerger's Disease in the U.S. and, in Japan, recipient of a SAKIGAKE designation and eligible for early conditional approval for the treatment of critical limb ischemia ("CLI") and Buerger's Disease based on the results of an ongoing clinical trial; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease ("DKD). For more information, visit the company's website at www.caladrius.com
Charge Enterprises Inc. (OTC: CRGE)
Charge Enterprises Inc. (OTC: CRGE) has a mission of connecting people everywhere with a strategy that incorporates telecom network infrastructure, connected calls, power banks and charging for electric vehicles. Trading on the OTC with an application recently submitted to the Nasdaq for uplisting, Charge Enterprises is a public company that shares its success with all stakeholders. The company operates in three distinct divisions through a number of recently acquired, or newly formed subsidiaries, including Charge Communications, Chare Infrastructure, Charge Investment and ANS Advanced Network Services. The management team is focused on the unglamorous part of connecting calls and powering the future of movement. For more information, visit the company's website at www.charge.us
Cocrystal Pharma (NASDAQ: COCP)
Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For more information, visit the company's website at www.cocrystalpharma.com
Crown Electrokinetics Corp. (NASDAQ: CRKN)
Crown Electrokinetics Corp. (NASDAQ: CRKN) is a smart glass technology company and the creator of DynamicTint - We Make Your Glass Smarter™. Originally invented by Hewlett-Packard (HP, Inc.), their technology allows any glass surface to transition between clear and dark in seconds. With applications to a wide array of windows, including commercial buildings, automotive sunroofs, and residential skylights, they partner with leading glass and film manufacturers for mass production and distribution. At the core of their technology is a thin film that is powered by electrically-charged pigment which not only replaces common window tints but is also a more sustainable alternative to traditional window treatments. With its unique ability to be retrofitted to existing glass, DynamicTint™ offers myriad benefits related to reducing carbon emissions. The company is supported by a robust patent portfolio. For more information, visit the company's website at www.crownek.com
Fortress Biotech, Inc. (NASDAQ: FBIO)
Fortress Biotech, Inc. (NASDAQ: FBIO) is an innovative biopharmaceutical company that was ranked in Deloitte's 2019 and 2020 Technology Fast 500™, annual rankings of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children's Research Hospital, Nationwide Children's Hospital and Sentynl Therapeutics, Inc. For more information, visit the company's website at www.fortressbiotech.com
Genius Brands International, Inc. (NASDAQ: GNUS)
Genius Brands International, Inc. (NASDAQ: GNUS) is a leading global kids media company developing, producing, marketing and licensing branded children's entertainment properties and consumer products for media and retail distribution. The Company's 'content with a purpose' portfolio includes Stan Lee's Superhero Kindergarten, starring Arnold Schwarzenegger, on Kartoon Channel!; Shaq's Garage, starring Shaquille O'Neal on Kartoon Channel!; Rainbow Rangers on Kartoon Channel! and Netflix; Llama Llama, starring Jennifer Garner, on Netflix; award-winning toddler brand Baby Genius; adventure comedy STEM series Thomas Edison's Secret Lab; and entrepreneurship series Warren Buffett's Secret Millionaires Club. Through licensing agreements with leading partners, characters from Genius Brands' IP also appear on a wide range of consumer products for the worldwide retail marketplace. The Company's Kartoon Channel! and Kartoon Classroom! are available in over 100 million U.S. television households via a broad range of distribution platforms, including Comcast, Cox, DISH, Sling TV, Amazon Prime, Amazon Fire, Apple TV, Apple iOS, Android TV, Android Mobil, Google Play, Xumo, Roku, Tubi, YouTube, KartoonChannel.com, Samsung Smart TVs and LG TVs. For more information, visit the company's website at www.gnusbrands.com
Helius Medical Technologies (NASDAQ: HSDT)
Helius Medical Technologies (NASDAQ: HSDT) is a neurotech company focused on neurological wellness. The Company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit the company's website at www.heliusmedical.com
Longeveron Inc. (NASDAQ: LGVN)
Longeveron Inc. (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B™ cell-based therapy product ("Lomecel-B"), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer's disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company's mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community. For more information, visit the company's website at www.longeveron.com
Milestone Scientific Inc. (NYSE: MLSS)
Milestone Scientific Inc. (NYSE: MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific's computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Milestone Scientific's proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. For more information, visit the company's website at milestonescientific.com
Oblong (NASDAQ: OBLG)
Oblong (NASDAQ: OBLG) provides innovative and patented technologies that change the way people work, create, and communicate. Oblong's flagship product MezzanineTM is a remote meeting technology platform that offers simultaneous content sharing to achieve situational awareness for both in-room and remote collaborators. Oblong supplies Mezzanine systems to Fortune 500 enterprise customers and is a Cisco Solutions Plus integration partner. For more information, visit the company's website at www.oblong.com
PainReform (NASDAQ: PRFX)
PainReform (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, visit the company's website at www.painreform.com
Profire Energy (NASDAQ: PFIE)
Profire Energy (NASDAQ: PFIE) assists energy production companies in the safe and efficient production and transportation of oil and natural gas. As energy companies seek greater safety for their employees, compliance with more stringent regulatory standards, and enhanced margins with their energy production processes, Profire Energy's burner management products are continuing to be a key part of their solutions. Profire Energy has offices in Lindon, Utah; Victoria, Texas; Homer, Pennsylvania; Greeley, Colorado; Millersburg, Ohio; and Acheson, Alberta, Canada. For more information, visit the company's website at www.profireenergy.com
Sorrento Therapeutics Inc. (NASDAQ: SRNE)
Sorrento Therapeutics Inc. (NASDAQ: SRNE) is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), immuno-cellular therapies ("DAR-T™"), antibody-drug conjugates ("ADCs"), and oncolytic virus ("Seprehvec™"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™. For more information, visit the company's website at www.sorrentotherapeutics.com
SRAX (NASDAQ: SRAX)
SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors' behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information, visit the company's website at srax.com